Hypoxia-mediated fenretinide (4-HPR) resistance in childhood acute lymphoblastic leukemia cells

By Yang Bo   Fan Lingling   Fang Liang   He Qiaojun  

Cancer Chemotherapy and Pharmacology, Vol. 58, Iss. 4, 2006-10 ,pp. : 540-546

Springer Publishing Company

Access to resources Recommend Favorite

Metabolism of N-[4-hydroxyphenyl]retinamide (4-HPR) to N-[4-methoxyphenyl]retinamide (4-MPR) may serve as a biomarker for its efficacy against human breast cancer and melanoma cells

By Mehta R.R.   Hawthorne M.E.   Graves J.M.   Mehta R.G.  

European Journal of Cancer, Vol. 34, Iss. 6, 1998-05 ,pp. : 902-907

Elsevier

Access to resources Recommend Favorite

Pharmacokinetics of oral fenretinide in neuroblastoma patients: indications for optimal dose and dosing schedule also with respect to the active metabolite 4-oxo-fenretinide

By Formelli Franca   Cavadini Elena   Luksch Roberto   Garaventa Alberto   Villani Maria   Appierto Valentina   Persiani Stefano  

Cancer Chemotherapy and Pharmacology, Vol. 62, Iss. 4, 2008-09 ,pp. : 655-665

Springer Publishing Company

Access to resources Recommend Favorite

Colorectal polyp model established by transplacental BMP4 RNAi

By              

Molecular Medicine Reports, Vol. 10, Iss. 1, 2014-01 ,pp. : 33-38

Spandidos Publications

Access to resources Recommend Favorite

Effects of Chronic Administration of N-(4-hydroxyphenyl)retinamide (4-HPR) in Rats on Vitamin A Metabolism in the Eye

By Lewis K.C.   Zech L.A.   Phang J.M.  

European Journal of Cancer, Vol. 32, Iss. 10, 1996-09 ,pp. : 1803-1808

Elsevier

Access to resources Recommend Favorite